HIMS my 2 cents on earnings. Beat top and bottom, which everyone likes to see. CF continues to grow, as well as subscriptions and $ per user. Opportunities within menopause and low testosterone products later this year, as well further partnerships with farmaceuticals (like Novo), without limiting the prescribed compounded products available. 2030 estimates for rev and ebitda growth will likely be met 2029 or earlier, just like the ones projected for 2024, which would imply 30% growth over the next years. Great stock to own, not a good day to buy. RSI got into overbought territory due to the short squeeze that's in motion. Cheers and take care everybody. FED meeting later this week.
82W Profit taking from the recent pump in motion, yet, RSI 1D not yet overbought. Keep calm for earnings. Only afterwards we can currently assess future prospects and the possibility of a pump. Good apointment for COO
HIMS curious about those earnings. Let's see if it's worth the pump. Good luck to all shareholders. If earnings prove to be good, might double down on this baby